Atrophy of Muscle Due to DisuseMACNCT04151901
Sex-specific Determinants of Early-phase Recovery From Skeletal Muscle Disuse
A study testing Resistance Exercise Rehabilitation and Walking-based rehabilitation in people with Atrophy of Muscle Due to Disuse and Rehabilitation, run by The University of Texas Health Science Center at San Antonio at 2 sites in United States.
Trial summary
This project is a 2-phase, randomized clinical trial that includes 7 days of unilateral leg disuse (Phase 1), immediately followed by 1 week of bilateral leg rehabilitation (Phase 2). Read more about this study
- Who is it for?
- Ages 50 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Atrophy of Muscle Due to Disuse, Rehabilitation
- What is being tested?
- Resistance Exercise Rehabilitation and Walking-based rehabilitation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 37 participants
- Where
- 2 sitesUnited States
- Study dates
- 27 Aug 2021to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- All races and ethnic backgrounds
- Men and women, age 50-65 years
- Generally healthy (see exclusion criteria)
- Able and willing to provide informed consent
- Ability to speak and read English
- Post-menopausal women (no menses within the last 12 months)
- Body mass index: 18.5-35 kg/m2 or BMI>35 if thigh adiposity does not impair muscle biopsy
Who cannot join
- Compromised musculoskeletal function that precludes safe participation or use of crutches
- Pre-menopausal women
- Hypogonadal men (testosterone <300 ng/dL)
- Women taking hormone replacement therapy (HRT)
- Sarcopenia (European Working Group on Sarcopenia in Older People, EWGSOP102)
- Clinically significant heart disease (e.g. New York Heart Classification greater than grade II; ischemia)
Show all 29Show fewer
- Peripheral vascular disease
- History of claudication
- Pulmonary disease
- History of systemic or pulmonary embolus
- Uncontrolled blood pressure (systolic BP>170, diastolic BP>95 mmHg)
- Impaired renal function (creatinine >1.5 mg/dl)
- Anemia (hematocrit <33)
- Untreated thyroid disease (abnormal TSH)
- A recent history (<12 months) of GI bleed
- Diabetes mellitus or other untreated endocrine or metabolic disease
- Electrolyte abnormalities
- Any history of stroke, hypo- or hyper-coagulation disorders
- Employment requiring long (>1 h) uninterrupted period of standing
- Inability to meet study travel requirements (e.g. manual geared car)
- Recent history of balance issues or falls.
- Recent (3 years) treated cancer other than basal cell carcinoma
- Systemic steroids, anabolic steroids, growth hormone or immunosuppressant use within 12 months
- Recent (2 months) adherence to a weight-loss or weight-gain diet
- Weight change of 5% or more in previous 6 months
- Body mass index >30 or excess body fat that compromises muscle biopsy collection
- Acute infectious disease or chronic infection
- Alcohol or drug abuse
- Any other condition or event considered exclusionary by study physician
Trial locations and contacts
2 sites in 1 country.
United States2 sites
University of Texas Medical Branch
Galveston, Texas, 77555
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229
About this study
This project is a 2-phase, randomized clinical trial that includes 7 days of unilateral leg disuse (Phase 1), immediately followed by 1 week of bilateral leg rehabilitation (Phase 2). The investigators will recruit cohorts of healthy middle-aged men and women to address their aims:
- Demonstrate the sex-specific effects of skeletal muscle disuse (Phase 1)
- Identify key molecular determinates of susceptibility of skeletal muscle atrophy (Phase 1)
- Map the early, sex-specific molecular time-course of rehabilitation (Phase 2)
- Determine if disused and healthy muscle respond similarly to exercise (Phase 2)
Read more
Healthy, middle-age men and post-menopausal women (50-65 years) will be recruited from the greater Houston/Galveston area. This under-represented research demographic demonstrate few negative metabolic or phenotypic signs of advanced age, but are at increased risk of being hospitalized and experiencing accelerated loss of lean mass and muscle function that parallels a much older population.
The goal of this study is to characterize phenotypic and molecular skeletal muscle changes in middle-aged men and women during critical periods of disuse and rehabilitation and ultimately direct the development of targeted and effective prevention and treatment strategies.
Read the detailed description
The negative health consequences of muscular disuse in aging populations are unequivocal. While descriptive, outcome data on disuse and recovery are abundant, key knowledge gaps limit researcher's ability to implement evidence-based, rehabilitation strategies. Limiters include: i) an inability to identify individuals most susceptible to disuse, ii) insufficient information to differentiate between, and respond to, disuse atrophy in men and women, iii) limited insight into the mechanisms driving adaptation to early rehabilitative exercise, and iv) the assumption that disused and healthy skeletal muscle will have a similar, positive response to resistance exercise. The investigators will complete a 2-phase, randomized clinical trial. The protocol includes 7-days of unilateral leg disuse (ULD; Phase 1), immediately followed by 1 week of bilateral leg rehabilitation (Phase 2). Healthy, middle-aged men (n=40) and (post-menopausal) women (n=40), (50-65 y) will be recruited; a neglected research demographic who present with a largely youthful phenotype, but are at risk of accelerated disuse atrophy.
This project will provide a highly powered, detailed phenotypic characterization of the continuum of adults most and least susceptible to muscular disuse. Clinical outcomes will be supported by RNA deep sequencing and pathway analysis to establish a platform that: i) improves scientists' ability to identify higher-risk individuals and ii) provides insight into time-sensitive, sex-specific and effective rehabilitation strategies. Findings and reposed molecular data from this study, may help identify future therapeutic targets and serve as an uncomplicated/comorbidity-free baseline for clinical trials in populations experiencing disuse atrophy.
- Conditions
- Atrophy of Muscle Due to Disuse, Rehabilitation
- Being tested
- Resistance Exercise Rehabilitation, Walking-based rehabilitation
- Medical subject headings
- Muscular Disorders, Atrophic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resistance Exercise RehabilitationOther
Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.
Walking-based rehabilitationOther
Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.
| Study group | Role | What they receive |
|---|---|---|
| Male Rehabilitation (M-REHAB) | Experimental | Disuse + resistance exercise rehabilitation Receives: Other: Resistance Exercise Rehabilitation |
| Male Control (M-CON) | Experimental | Disuse + ambulatory control rehabilitation Receives: Other: Walking-based rehabilitation |
| Female Rehabilitation (F-REHAB) | Experimental | Disuse + resistance exercise rehabilitation Receives: Other: Resistance Exercise Rehabilitation |
| Female Control (F-CON) | Experimental | Disuse + ambulatory control rehabilitation Receives: Other: Walking-based rehabilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quantitative RNA-sequencing
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Measured: Study day 1 (before starting leg disuse)
Quantitative RNA-sequencing
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Measured: Study day 7 (after finishing leg disuse)
Quantitative RNA-sequencing
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Measured: Study day 7 (after 1 bout of rehabilitation)
Quantitative RNA-sequencing
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Measured: Study day 9 (after 2 bouts of rehabilitation)
Quantitative RNA-sequencing
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Measured: Study Day 11 (after 3 bouts of rehabilitation)
Quantitative RNA-sequencing
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Measured: Study Day 21 (after finishing 7 bouts of rehabilitation)
Muscle function
Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)
Measured: Study day 1 (before starting leg disuse)
Muscle function
Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)
Measured: Study day 7 (after 1 bout of rehabilitation)
Muscle function
Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)
Measured: Study day 9 (after 2 bouts of rehabilitation)
Muscle function
Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)
Measured: Study Day 11 (after 3 bouts of rehabilitation)
Muscle function
Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)
Measured: Study Day 21 (after finishing 7 bouts of rehabilitation)
Body (leg) composition
Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry
Measured: Study day 1 (before starting leg disuse)
Body (leg) composition
Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry
Measured: Study day 7 (after finishing leg disuse)
Body (leg) composition
Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry
Measured: Study day 9 (after 2 bouts of rehabilitation)
Body (leg) composition
Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry
Measured: Study Day 11 (after 3 bouts of rehabilitation)
Body (leg) composition
Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry
Measured: Study Day 21 (after finishing 7 bouts of rehabilitation)
Secondary outcomes (15)
Muscle fiber cross sectional area
Muscle biopsy samples will be evaluated for muscle fiber cross sectional area
Measured: Study day 1 (before starting leg disuse)
Muscle fiber cross sectional area
Muscle biopsy samples will be evaluated for muscle fiber cross sectional area
Measured: Study day 7 (after finishing leg disuse)
Muscle fiber cross sectional area
Muscle biopsy samples will be evaluated for muscle fiber cross sectional area
Measured: Study day 9 (after 2 bouts of rehabilitation)
Muscle fiber cross sectional area
Muscle biopsy samples will be evaluated for muscle fiber cross sectional area
Measured: Study Day 11 (after 3 bouts of rehabilitation)
Muscle fiber cross sectional area
Muscle biopsy samples will be evaluated for muscle fiber cross sectional area
Measured: Study Day 21 (after finishing 7 bouts of rehabilitation)
Muscle fiber type
Muscle biopsy samples will be evaluated for muscle fiber type distribution
Measured: Study day 1 (before starting leg disuse)
Muscle fiber type
Muscle biopsy samples will be evaluated for muscle fiber type distribution
Measured: Study day 7 (after finishing leg disuse)
Muscle fiber type
Muscle biopsy samples will be evaluated for muscle fiber type distribution
Measured: Study day 9 (after 2 bouts of rehabilitation)
Muscle fiber type
Muscle biopsy samples will be evaluated for muscle fiber type distribution
Measured: Study Day 11 (after 3 bouts of rehabilitation)
Muscle fiber type
Muscle biopsy samples will be evaluated for muscle fiber type distribution
Measured: Study Day 21 (after finishing 7 bouts of rehabilitation)
Diet recall
A multi-pass 24-hour dietary recall using the Automated Self Assessment 24-h dietary assessment tool to determine habitual food intake
Measured: Familiarization session (~1 week before starting leg disuse)
Diet recall
A multi-pass 24-hour dietary recall using the Automated Self Assessment 24-h dietary assessment tool to determine habitual food intake
Measured: Study day 11 (after two bouts of rehabilitation)
Physical activity
Accelerometers will placed on the waist and ankle to measure physical activity
Measured: Study Days -7 to Day 0 (1 week prior to starting leg disuse)
Physical activity
Accelerometers will placed on the waist and ankle to measure physical activity
Measured: Study Days 1-6 (1 week of disuse)
Physical activity
Accelerometers will placed on the waist and ankle to measure physical activity
Measured: Study Days 7-21 (2 weeks of rehabilitation)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2019
- Study start27 Aug 2021
- Primary completion31 Mar 2026
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrophy of Muscle Due to DisuseStudies of the same condition, open and under way.
- More trials run by The University of Texas Health Science Center at San AntonioThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 37 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Responsible party
- Sponsor
- Investigators
- Blake Rasmussen, PhD, Principal investigator, University of Texas Health Science Center as San Antonio
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04151901
- Sponsor's protocol ID
- HSC20230594H
- Other IDs
- R01AG064386
- Acronym
- MAC
- Status last verified
- Jun 2026
- First submitted
- 9 Oct 2019
- Last updated
- 4 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected de-identified Individual Participant Data (IPD) that underlie results in a publication. Biological samples will not be available to other/outside investigators, but may be used by the research team for future related assays and experiments.
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sex-specific Determinants of Early-phase Recovery From Skeletal Muscle Disuse
- ClinicalTrials.gov ID
- NCT04151901
- Acronym / sponsor ID
- MAC / HSC20230594H
- Conditions
- Atrophy of Muscle Due to Disuse, Rehabilitation
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 37 participants (actual)
- Lead sponsor
- The University of Texas Health Science Center at San AntonioUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Study start
- 27 Aug 2021 (actual)
- Primary completion
- 31 Mar 2026 (actual)
- Study completion
- Dec 2026 (estimated)
- First posted
- 5 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project is a 2-phase, randomized clinical trial that includes 7 days of unilateral leg disuse (Phase 1), immediately followed by 1 week of bilateral leg rehabilitation (Phase 2). The investigators will recruit cohorts of healthy middle-aged men and women to address their aims:
- Demonstrate the sex-specific effects of skeletal muscle disuse (Phase 1)
- Identify key molecular determinates of susceptibility of skeletal muscle atrophy (Phase 1)
- Map the early, sex-specific molecular time-course of rehabilitation (Phase 2)
- Determine if disused and healthy muscle respond similarly to exercise (Phase 2)
Healthy, middle-age men and post-menopausal women (50-65 years) will be recruited from the greater Houston/Galveston area. This under-represented research demographic demonstrate few negative metabolic or phenotypic signs of advanced age, but are at increased risk of being hospitalized and experiencing accelerated loss of lean mass and muscle function that parallels a much older population.
The goal of this study is to characterize phenotypic and molecular skeletal muscle changes in middle-aged men and women during critical periods of disuse and rehabilitation and ultimately direct the development of targeted and effective prevention and treatment strategies.
Detailed description
The negative health consequences of muscular disuse in aging populations are unequivocal. While descriptive, outcome data on disuse and recovery are abundant, key knowledge gaps limit researcher's ability to implement evidence-based, rehabilitation strategies. Limiters include: i) an inability to identify individuals most susceptible to disuse, ii) insufficient information to differentiate between, and respond to, disuse atrophy in men and women, iii) limited insight into the mechanisms driving adaptation to early rehabilitative exercise, and iv) the assumption that disused and healthy skeletal muscle will have a similar, positive response to resistance exercise. The investigators will complete a 2-phase, randomized clinical trial. The protocol includes 7-days of unilateral leg disuse (ULD; Phase 1), immediately followed by 1 week of bilateral leg rehabilitation (Phase 2). Healthy, middle-aged men (n=40) and (post-menopausal) women (n=40), (50-65 y) will be recruited; a neglected research demographic who present with a largely youthful phenotype, but are at risk of accelerated disuse atrophy.
This project will provide a highly powered, detailed phenotypic characterization of the continuum of adults most and least susceptible to muscular disuse. Clinical outcomes will be supported by RNA deep sequencing and pathway analysis to establish a platform that: i) improves scientists' ability to identify higher-risk individuals and ii) provides insight into time-sensitive, sex-specific and effective rehabilitation strategies. Findings and reposed molecular data from this study, may help identify future therapeutic targets and serve as an uncomplicated/comorbidity-free baseline for clinical trials in populations experiencing disuse atrophy.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (participant)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Male Rehabilitation (M-REHAB) | Experimental | Other: Resistance Exercise RehabilitationDisuse + resistance exercise rehabilitation |
| Male Control (M-CON) | Experimental | Other: Walking-based rehabilitationDisuse + ambulatory control rehabilitation |
| Female Rehabilitation (F-REHAB) | Experimental | Other: Resistance Exercise RehabilitationDisuse + resistance exercise rehabilitation |
| Female Control (F-CON) | Experimental | Other: Walking-based rehabilitationDisuse + ambulatory control rehabilitation |
Who may qualify
- Ages
- 50 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- All races and ethnic backgrounds
- Men and women, age 50-65 years
- Generally healthy (see exclusion criteria)
- Able and willing to provide informed consent
- Ability to speak and read English
Key exclusion criteria (29 listed)
- Compromised musculoskeletal function that precludes safe participation or use of crutches
- Pre-menopausal women
- Hypogonadal men (testosterone <300 ng/dL)
- Women taking hormone replacement therapy (HRT)
- Sarcopenia (European Working Group on Sarcopenia in Older People, EWGSOP102)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resistance Exercise RehabilitationFollowing disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit. | Other | Female Rehabilitation (F-REHAB), Male Rehabilitation (M-REHAB) |
| Walking-based rehabilitationFollowing disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit. | Other | Female Control (F-CON), Male Control (M-CON) |
Primary outcome
Quantitative RNA-sequencing
Time frame: Study day 1 (before starting leg disuse)
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Quantitative RNA-sequencing
Time frame: Study day 7 (after finishing leg disuse)
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Quantitative RNA-sequencing
Time frame: Study day 7 (after 1 bout of rehabilitation)
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Quantitative RNA-sequencing
Time frame: Study day 9 (after 2 bouts of rehabilitation)
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Quantitative RNA-sequencing
Time frame: Study Day 11 (after 3 bouts of rehabilitation)
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Quantitative RNA-sequencing
Time frame: Study Day 21 (after finishing 7 bouts of rehabilitation)
RNA deep sequence analysis on muscle tissue taken from a muscle biopsy to measure transcriptome
Muscle function
Time frame: Study day 1 (before starting leg disuse)
Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)
Muscle function
Time frame: Study day 7 (after 1 bout of rehabilitation)
Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)
Muscle function
Time frame: Study day 9 (after 2 bouts of rehabilitation)
Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)
Muscle function
Time frame: Study Day 11 (after 3 bouts of rehabilitation)
Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)
Muscle function
Time frame: Study Day 21 (after finishing 7 bouts of rehabilitation)
Each leg will be individually tested on an isokinetic dynamometer to determine muscle strength (peak torque)
Body (leg) composition
Time frame: Study day 1 (before starting leg disuse)
Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry
Body (leg) composition
Time frame: Study day 7 (after finishing leg disuse)
Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry
Body (leg) composition
Time frame: Study day 9 (after 2 bouts of rehabilitation)
Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry
Body (leg) composition
Time frame: Study Day 11 (after 3 bouts of rehabilitation)
Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry
Body (leg) composition
Time frame: Study Day 21 (after finishing 7 bouts of rehabilitation)
Leg lean mass will be assessed via segmental dual energy x-ray absorptiometry
15 secondary outcomes
Muscle fiber cross sectional area
Time frame: Study day 1 (before starting leg disuse)
Muscle fiber cross sectional area
Time frame: Study day 7 (after finishing leg disuse)
Muscle fiber cross sectional area
Time frame: Study day 9 (after 2 bouts of rehabilitation)
Muscle fiber cross sectional area
Time frame: Study Day 11 (after 3 bouts of rehabilitation)
Muscle fiber cross sectional area
Time frame: Study Day 21 (after finishing 7 bouts of rehabilitation)
Muscle fiber type
Time frame: Study day 1 (before starting leg disuse)
Muscle fiber type
Time frame: Study day 7 (after finishing leg disuse)
Muscle fiber type
Time frame: Study day 9 (after 2 bouts of rehabilitation)
Muscle fiber type
Time frame: Study Day 11 (after 3 bouts of rehabilitation)
Muscle fiber type
Time frame: Study Day 21 (after finishing 7 bouts of rehabilitation)
Diet recall
Time frame: Familiarization session (~1 week before starting leg disuse)
Diet recall
Time frame: Study day 11 (after two bouts of rehabilitation)
Physical activity
Time frame: Study Days -7 to Day 0 (1 week prior to starting leg disuse)
Physical activity
Time frame: Study Days 1-6 (1 week of disuse)
Physical activity
Time frame: Study Days 7-21 (2 weeks of rehabilitation)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2026.
- Individual participant dataSharing planned: Yes. All collected de-identified Individual Participant Data (IPD) that underlie results in a publication. Biological samples will not be available to other/outside investigators, but may be used by the research team for future related assays and experiments.
Related trials for Atrophy of Muscle Due to Disuse
Not yet recruiting
Effect of Knee Position on Muscle Loss During Leg Immobilization
Muscle Atrophy, Disuse Atrophy
Not yet recruiting
Cross-education of Skill and Strength in Healthy People Subjected to an Upper-limb Disuse Model
Disuse Atrophy, Immobilization
Recruiting
Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength
Chronic Kidney Disease (CKD)
Recruiting
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men
Mitochondrial Energetics, Dietary Nitrate
Recruiting
Human Skeletal Muscle Response to 5 Days of Bedrest in Young Adults
Muscular Atrophy, Insulin Resistance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Blake Rasmussen, PhD principal investigator
University of Texas Health Science Center as San Antonio
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resistance Exercise Rehabilitation and Walking-based rehabilitation in people with Atrophy of Muscle Due to Disuse and Rehabilitation, run by The University of Texas Health Science Center at San Antonio at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quantitative RNA-sequencing (time frame: Study day 1 (before starting leg disuse)). The study lists 16 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.